Valeant Pharmaceuticals Price Target Raised to $146.00 at BMO Capital Markets (VRX)
Equities research analysts at BMO Capital Markets boosted their price target on shares of Valeant Pharmaceuticals (NYSE:VRX) from $132.00 to $146.00 in a research note issued to investors on Wednesday, Stock Ratings Network.com reports. BMO Capital Markets’ target price suggests a potential upside of 13.80% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of Valeant Pharmaceuticals from $115.00 to $119.00 in a research note to investors on Tuesday, December 17th. Separately, analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals from $115.00 to $125.00 in a research note to investors on Tuesday, December 3rd. They now have a “buy” rating on the stock. Finally, analysts at Zacks downgraded shares of Valeant Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, November 6th. They now have a $116.40 price target on the stock. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $127.96.
Shares of Valeant Pharmaceuticals (NYSE:VRX) traded up 2.35% on Wednesday, hitting $128.30. 3,025,998 shares of the company’s stock traded hands. Valeant Pharmaceuticals has a 52 week low of $62.80 and a 52 week high of $135.73. The stock’s 50-day moving average is $111.5 and its 200-day moving average is $103.4. The company’s market cap is $42.838 billion.
Valeant Pharmaceuticals (NYSE:VRX) last announced its earnings results on Thursday, October 31st. The company reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.11. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $884.14 million. During the same quarter in the previous year, the company posted $1.15 earnings per share. The company’s revenue for the quarter was up 74.4% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals will post $6.13 EPS for the current fiscal year.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.